Scienture Partners with BlinkRx for Arbli™ Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 Dec 25
Scienture Holdings Inc's stock fell by 5.05%, crossing below the 5-day SMA amid broader market gains.
The company announced a partnership with BlinkRx to launch Arbli™, a new FDA-approved oral suspension of losartan, expected to be available in Q1 2026. This innovative product aims to improve patient access and adherence, addressing a significant market opportunity in the U.S. losartan market.
This collaboration reflects Scienture's commitment to enhancing patient experiences and could drive future prescription volume growth, despite the current stock decline.
Analyst Views on SCNX
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
